The selective synergy observed in IDH1 WT backgrounds, particularly with the compound 2/TMZ combination, suggests that IDH1 mutation status modulates the efficacy of RNaseH2 inhibition, meriting further investigation in genetic models that further reflect glioma diversity. This evidence concerns the gene IDH1 and central nervous system cancer.